Report highlights latest in COPD research and treatments

Graphic of a book cover 'Chronic Obstructive Pulmonary Disease Pipeline'

More than 60 companies and 70 drugs are leading the way when it comes to research into novel treatments for COPD.

That’s according to the “Chronic Obstructive Pulmonary Disease – Pipeline Insight 2023” report issued in July.

The report includes a comprehensive overview of pipeline drug profiles, including clinical and non-clinical stage products as well as a thorough assessment of therapeutics such as product type, stage, route of administration and molecule type.

Among the highlights are emerging drugs such as benralizumab from AstraZeneca and dupilumab from Sanofi.

Benralizumab is a humanized recombinant monoclonal antibody that specifically binds to the alpha chain of the interleukin-5 receptor expressed on eosinophils and basophils. It inhibits the binding of IL-5, thus blocking signal transduction.

Earlier this year, Sanofi and Regeneron Pharmaceuticals announced that dupilumab, which is currently in phase 3 trials, is the first biologic to demonstrate a clinically meaningful and statistically significant reduction (30%) in exacerbations compared to a placebo.

Another emerging drug in 2023 is tezepelumab (Tezspire), which is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium. This area is the first point of contact for viruses, allergens, pollutants and other environmental attacks on the system.

Tezspire targets and blocks a key epithelial cytokine that sits on top of multiple inflammatory cascades and initiates an overreactive immune response to airway inflammation associated with severe asthma and COPD.

The report also includes therapeutic assessment of the different COPD drugs, an overview of unmet needs in COPD treatment and a rundown of the impact these drugs will have on treatment.   

More in COPD
Page 1 of 13
Next Page